Olink®Part of Thermo Fisher Scientific
Powerful, NGS-based proteomics - effortlessly uncover meaningful insights
A unique combination of specificity and scalability enables high-throughput, multiplex protein biomarker analysis.
Next-generation high-throughput proteomics empowers genetically-informed assessment of protein causality and the confident identification of novel drug targets.
Join the growing global community and consortia of Olink users to empower your biomarker discovery.
Over 2,900 and growing rapidly – covering all major disease areas
Your source for Olink’s terms, privacy policies, and compliance details
Filters
Nature Communications, 2025FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma
Beffinger M., Schellhammer L., Taskoparan B. et al.
Olink Target 96
The American Journal of Clinical Nutrition, 2025Relationship of healthy lifestyle with healthy aging and the mediation by plasma proteins: a prospective cohort study
Fang F., Liu Z., Lyu J. et al.
Olink Explore 3072/384
Medicine, 2025Roles of plasma proteins in mediating the causal effect of the lipid species on gastric cancer: Insights from proteomic and two-step Mendelian randomization
Dong Z., Chen Z., Yu K. et al.
Journal of Interferon & Cytokine Research, 2025Significant Associations Between Blood Cell Counts and a Large Number of Salivary Cytokines, Chemokines, and Growth Factors
Eriksson L., Eriksson M., Gordh T. et al.
Nature Communications, 2025In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome
Mizumaki H., Gao S., Wu Z. et al.
Blood Journal, 2025Ruxolitinib Targets JAK-STAT Signaling to Modulate Neutrophil Activation in Refractory Macrophage Activation Syndrome
Ma Y., Chen X., Wang M. et al.
Allergy, 2025Deciphering the Connection Between Atopic Dermatitis and Cardiovascular Diseases: Analysis of Clinical Associations and Cardiometabolic Proteins
Fehr D., Huynh‐Tran V., Maintz L. et al.
Brain and Behavior, 2025Causal Relationships Between the Gut Microbiota, Inflammatory Cytokines, and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Analysis
Changqing L., Leying Y., Caiyun M. et al.
Discover Oncology, 2025Exploring the causal relationship between immune factors and chondrosarcoma: a Mendelian randomization study
Xu T., Xiao W., Li W. et al.
European Journal of Endocrinology, 2025Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases
Wu J., Wu G., Li J. et al.
Nature Communications, 2025SARS-CoV-2 induced immune perturbations in infants vary with disease severity and differ from adults’ responses
Nehar-Belaid D., Mejías A., Xu Z. et al.
Scientific Reports, 2025The contribution of oral infectious diseases in lacunar stroke based on meta-analysis and Mendelian randomization study
Zheng Q., Xu T., Luo S. et al.
Frontiers in Immunology, 2025Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology
Zhou X., Wang W., Chen L. et al.
Aging Cell, 2025Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Mury P., Dagher O., Fortier A. et al.
Journal of the American Heart Association, 2025IL1RAP Expression in Human Atherosclerosis: A Target of Novel Antibodies to Reduce Vascular Inflammation and Adhesion
Lindkvist M., Göthlin Eremo A., Paramel G. et al.
Journal of the American Heart Association, 2025Circulating Proteomics Identifies a Dynamic Profile of Hepatic Steatosis During Metabolic Intervention
El‐Sabawi B., Tanriverdi K., Gajjar P. et al.
Journal of the American Heart Association, 2025Systemic Changes in Adults With a Fontan Circulation: Insights From the Plasma Proteome
Kelly B., Ravndal M., Bach P. et al.
The Oncologist, 2025First-in-human phase I open-label study of the anti–TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors
Gutierrez M., Tang S., Powderly J. et al.
The Oncologist, 2025First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors
Powderly J., Gutierrez M., Balmanoukian A. et al.
Nature, 2025Interferon-γ orchestrates leptomeningeal anti-tumour response
Remsik J., Tong X., Kunes R. et al.
2965 publications
Items per page
201-220 of 2965 publications